HK1206995A1 - Methods for increasing cftr activity - Google Patents

Methods for increasing cftr activity Download PDF

Info

Publication number
HK1206995A1
HK1206995A1 HK15107706.3A HK15107706A HK1206995A1 HK 1206995 A1 HK1206995 A1 HK 1206995A1 HK 15107706 A HK15107706 A HK 15107706A HK 1206995 A1 HK1206995 A1 HK 1206995A1
Authority
HK
Hong Kong
Prior art keywords
increasing
mucociliary clearance
subject
compounds
present disclosure
Prior art date
Application number
HK15107706.3A
Other languages
English (en)
Chinese (zh)
Inventor
M. Rowe Steven
Dransfield Mark
Original Assignee
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Uab Research Foundation filed Critical The Uab Research Foundation
Publication of HK1206995A1 publication Critical patent/HK1206995A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15107706.3A 2012-04-06 2013-03-15 Methods for increasing cftr activity HK1206995A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621043P 2012-04-06 2012-04-06
US61/621,043 2012-04-06
PCT/US2013/032268 WO2013151758A2 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Publications (1)

Publication Number Publication Date
HK1206995A1 true HK1206995A1 (en) 2016-01-22

Family

ID=49301152

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107706.3A HK1206995A1 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Country Status (8)

Country Link
US (2) US20150065539A1 (https=)
EP (1) EP2833885A4 (https=)
JP (1) JP6525203B2 (https=)
CN (1) CN104619321A (https=)
AU (2) AU2013243857A1 (https=)
CA (1) CA2869257A1 (https=)
HK (1) HK1206995A1 (https=)
WO (1) WO2013151758A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
MX2011001782A (es) 2008-08-13 2012-02-08 Vertex Pharma Composicion farmaceutica y su administracion.
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2011030163A1 (en) * 2009-09-12 2011-03-17 Reckitt Benckiser Llc Use of guaifenesin for inhibiting mucin secretion
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
EP3037415A1 (en) * 2010-03-19 2016-06-29 Vertex Pharmaceuticals Inc. Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RS56096B1 (sr) * 2011-05-18 2017-10-31 Concert Pharmaceuticals Inc Deuterisani derivati ivakaftora

Also Published As

Publication number Publication date
US10300052B2 (en) 2019-05-28
EP2833885A4 (en) 2015-12-16
JP6525203B2 (ja) 2019-06-05
AU2018200192B9 (en) 2019-07-25
AU2013243857A1 (en) 2014-10-16
CA2869257A1 (en) 2013-10-10
WO2013151758A2 (en) 2013-10-10
JP2015521157A (ja) 2015-07-27
CN104619321A (zh) 2015-05-13
EP2833885A2 (en) 2015-02-11
US20170266177A1 (en) 2017-09-21
US20150065539A1 (en) 2015-03-05
AU2018200192B2 (en) 2019-06-06
AU2018200192A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
EP3066616A4 (en) Classification of activity derived from multiple locations
WO2014100764A3 (en) Methods of inhibiting prmt5
EP3398679A4 (en) Cluster supported catalyst and production method therefor
EP3036506A4 (en) Realtime activity suggestion from social and event data
EP3035800A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3038635A4 (en) Systems, compositions, and methods for transplantation and treating conditions
BR112014028751A2 (pt) partícula encapsulada, e, método para formar uma partícula encapsulada.
BR112014029288A2 (pt) métodos, sistemas e dispositivos para randomização de interferência desacoplada para sinais de referência de uplink
EP3093361A4 (en) Bearing component, steel for bearing component, and production method for same
BR112014031787A2 (pt) composição, métodos de substituição e para produção de refrigeração e equipamento de refrigeração.
BR112015011139A2 (pt) partícula encapsulada, e, método para formar uma partícula encapsulada.
EP3122459A4 (en) Methods and systems for forming catalytic assemblies, and related catalytic assemblies
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease
EP2843814A3 (en) Cover for slider of linear conveyer, linear conveyer, slider assembly, and method of detaching cover from slider of linear conveyer
DK3910337T3 (da) Fremgangsmåde til at katalysere en enzym-katalyseret reaktion
EP3068389A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
BR112015009275A2 (pt) aparelho para cozer produtos, e, método de cozimento de produtos.
EP3081299A4 (en) Catalyst for hydrocracking and hydrocarbon production method
SG11201403264SA (en) Fe-Pt-Ag-C-BASED SPUTTERING TARGET HAVING C PARTICLES DISPERSED THEREIN, AND METHOD FOR PRODUCING SAME
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
EP3028764A4 (en) Plate, production method for plate, biochip observation method, and screening method
EP3052662A4 (en) Compositions, systems and methods for gene expression noise drug screening and uses thereof
EP3186270A4 (en) Cyclic urea compounds as granzyme b inhibitors
CL2014002012A1 (es) Método y equipo para la producción de chocolate.
WO2014160628A3 (en) Articles and methods for preventing and treating dermatologic adverse events